Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, Reynosa 88710, Mexico.
Instituto de Quimica, Universidad Nacional Autonoma de Mexico, Cd. Universitaria, Circuito Exterior, Coyoacan, Ciudad de Mexico 04510, Mexico.
Curr Med Chem. 2021;28(3):583-606. doi: 10.2174/0929867327666200303170000.
Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low- and high-income countries and their pharmacological treatments are limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidazole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.
由布氏锥虫、克氏锥虫、利什曼原虫、溶组织内阿米巴、蓝氏贾第鞭毛虫、疟原虫和阴道毛滴虫引起的感染是人类寄生虫病的一大类。这些原生动物寄生虫每年导致超过 5 亿例感染。这些寄生虫病影响低收入和高收入国家，其药物治疗方法有限。因此，即使其作用机制未知，临床前开发的新的、更有效的药物也可以改善寄生虫感染的整体治疗效果。在这篇综述中，讨论了一些作为抗原生动物药物报道的杂环化合物（二脒、胍、喹啉、苯并咪唑、噻唑、二氮萘和它们的衍生物），作为开发寄生虫病新药物治疗方法的选择。
